The U.S Food and Drug Administration approved Tecnis Eyhance and Tecnis Eyhance Toric II IOLs ((Johnson & Johnson Vision) for the treatment of patients with cataracts, according to a press release.
“Eighty-four percent of surgeons choose monofocal IOLs for their cataract patients, so it’s thrilling to see the first breakthrough in monofocal technology in decades enter the market to add to our treatment portfolio,” said Douglas Koch, MD, Houston, a paid consultant of Johnson & Johnson Vision, Inc, in the press release. “It’s the first monofocal designed to provide a slight increase in the depth of focus, which is something I need for the patients in my practice looking for more from a monofocal.”
Read the full press release here.
Related Content
